Is JNJ stock finally ready to take off? – Magic Post

Is JNJ stock finally ready to take off?

 – Magic Post

Johnson & Johnson New York Stock Exchange: GNG The stock rose 1.8% in the five days after the company announced its $14.6 billion acquisition Intracellular Therapy Company Nasdaq: ITCI. The company will purchase all of the neuroscience company’s existing shares at a price of $132. This will be an all cash deal.

Johnson & Johnson today

Johnson & Johnson stock logo
JNJJNJ performance for 90 days

Johnson & Johnson

$147.03 -0.74 (-0.50%)

As of 01/17/2025 at 03:59 PM ET

52 week range
$140.68

$168.85

Dividend yield
3.37%

P/E ratio
21.28

Price target
$174.29

The deal will build on Johnson & Johnson’s 70 years of experience in neuroscience. Specifically, the company is now adding inside-Cellular Capleta® for its pharmaceutical portfolio. This is a once-daily pill that has been approved by the FDA to treat schizophrenia, and is the only FDA-approved medication to treat depressive episodes associated with bipolar depression. CAPLYTA is currently being reviewed for additional indications.

However, the acquisition also gives Johnson & Johnson access to Intra-Cellular’s promising clinical-stage pipeline that includes drugs to treat generalized anxiety disorder, psychosis, and agitation that can be part of Alzheimer’s disease.

Johnson & Johnson is clearly leaning toward mental health at a time when its importance has never carried more weight. However, after several years of deals, shareholders must wonder whether the attractive valuation is enough to consider JNJ shares in 2025.

Is it time for the company’s investments to pay off?

The biopharmaceutical industry is a adapt-or-die industry. Among medical stocks, Johnson & Johnson is well-equipped to thrive in this industry. In addition to its diverse pipeline, the company’s strong balance sheet allows it to grow through acquisition.

Intra-Cellular is the latest example of this, but it’s not the only deal JNJ has made in recent years. In 2024, the company paid $13.1 billion for Shockwave Medical, and in 2022, it bought Abiomed for $16.6 billion.

This year, Johnson & Johnson is expected to achieve revenues of $88.5 billion. This is about 4% lower than the previous year. The company’s ability to pay for these acquisitions is not in doubt, nor do they take a significant portion of the company’s profits. But it brings the company’s net debt to a somewhat uncomfortable level of 66%.

However, investors are turning to biopharmaceutical companies that produce GLP-1 drugs; Some may want Johnson & Johnson’s investments to pay off in revenue before assigning a distinct value to the stock. This is reflected in the wait-and-see approach to JNJ stock. The company holds the dubious distinction of being one of the Dow Jones’ “dogs” in 2024. In the past three years, the total return for JNJ stock has been negative 5.3%. This is especially concerning when you consider the company’s 3.3% dividend yield.

JNJ is objectively undervalued

Johnson & Johnson dividend payments

Dividend yield
3.37%

Annual profits
$4.96

Increasing track record profits
63 years old

Annual earnings growth for 3 years
5.43%

Dividend distribution ratio
71.78%

Upcoming dividend payment
March 4

JNJ Dividend History

While the average price-to-earnings (P/E) ratio of the S&P 500 is around 24.8 times, it’s worth noting that JNJ shares trade at an attractive forward earnings of 14.5 times as of January 15, 2025. The valuation comes with a dividend carrying A solid 3.3% return.

In fact, Johnson & Johnson is one of the companies that is part of the exclusive dividend kings. The company has been increasing its dividend for 62 consecutive years, and the company’s strong balance sheet supports those dividends.

With the stock down about 10% in 2024 compared to the S&P 500’s return of about 21%, there is room for JNJ to play catch-up as investors move away from technology stocks and look for areas of growth.

JNJ’s Road to Recovery: What Investors Should Watch

JNJ stock has been trading below its 50-day simple moving average (SMA) since late October. This coincided with the company’s third-quarter earnings report. However, as of midday trading on January 16, 2025, the stock is within 2% of that technically important mark.

A major catalyst for the stock could come when the company reports earnings on January 22nd. A significant break above this level may be a sign that investors are becoming more optimistic about the undervalued dividend king.

A break above the 50-day simple moving average may also coincide with Johnson & Johnson analyst forecasts on MarketBeat, which give JNJ stock a consensus price target of $174.41. This would give investors an 18.7% upside as well as a stable dividend.

Johnson & Johnson (JNJ) price chart for Saturday, January 18, 2025

Before you consider Johnson & Johnson, you’ll want to hear this.

MarketBeat tracks the highest-rated and best-performing research analysts on Wall Street and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches up… and Johnson & Johnson wasn’t on the list.

While Johnson & Johnson currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View the five stocks here

Gold Forecast for 2025: A Perfect Storm for Demand Coverage

Discover the eternal value of gold with our exclusive 2025 Gold Forecast. Find out why gold remains the ultimate investment for protecting wealth from inflation, economic shifts and global uncertainties. Whether you are planning for future generations or looking for reliable assets in turbulent times, this report is your essential guide to making informed decisions.

Get this free report

Like this article? Share it with a colleague.

The link has been copied to the clipboard.

Leave a Reply

Your email address will not be published. Required fields are marked *